Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Criteria: * Histologically and/or cytologically confirmed malignant pleural mesothelioma. * Unresectable disease (defined as the participant not being a candidate for curative surgery). * Measurable disease, defined as at least 1 lesion (measurable) that can be accurately assessed at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) and is suitable for repeated assessment (modified RECIST for pleural mesothelioma). * Available unstained archived tumor tissue sample in sufficient quantity to allow for analyses. At least fifteen unstained slides or a tumor block (preferred). NOTE: A fine needle aspiration sample is not sufficient to make the patient eligible for enrollment. Given the complexity of mesothelioma pathological diagnosis and that these will be newly diagnosed patients it is expected that they will have a core needle biopsy or surgical tumor biopsy as part of their initial diagnostic work up. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Ability to understand and willingness to sign Institutional Review Board (IRB)-approved informed consent. * Willing to provide archived tumor tissue and blood samples for research. * Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks prior to registration: * Absolute Neutrophil Count (ANC) ≥ 1500/mm³ * Hemoglobin ˃9.0 g/dL * Platelets ˃100,000/mm³ * Serum creatinine clearance (CL)\>60 mL/min by the Cockcroft-Gault formula or b…